PDS Biotechnology Corp (PDSB) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.88 (+4.55%), Market cap $0.06B, 52-week low–high $0.54 ~ $1.79.
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and l
Financial statements, price targets, institutional (13F) holdings and related news for PDS Biotechnology Corp are updated in real time on BlackAll Trade.
PDS Biotechnology Corp trades at $0.88 (+4.55%). Real-time quotes and charts are available on BlackAll Trade.
PDS Biotechnology Corp has a market cap of about $0.06B.
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS010